At the highest dose in a Phase 1 trial of 15 adults with refractory dyslipidemia, a single intravenous course of CTX310 cut circulating ANGPTL3 by a mean of 73% (max 89%), lowered triglycerides by a mean of 55% (max 84%), and reduced LDL cholesterol by a mean of 49% (max 87%) by Day 60. Among participants with baseline triglycerides above 150 mg/dL, mean triglyceride reductions reached 60% at therapeutic dose levels. No treatment-related serious adverse events or ≥Grade 3 transaminase elevations were reported; infusion reactions were Grade 2 and self-limited.
The core news is CRISPR Therapeutics’ first-in-human, in vivo CRISPR/Cas9 program, which delivered clinically meaningful lipid-lowering after a single LNP-delivered edit of ANGPTL3 in hepatocytes, with results presented at AHA and published in the New England Journal of Medicine. The open-label, dose-escalation study enrolled patients with HoFH, HeFH, severe hypertriglyceridemia, or mixed dyslipidemia inadequately controlled on background therapy; most were on statins and/or ezetimibe, and 40% were on PCSK9 inhibitors. The company plans to advance CTX310 into Phase 1b, prioritizing severe hypertriglyceridemia and mixed dyslipidemia.
Strategically, this is a direct challenge to the chronic-therapy paradigm that defines lipid management. By targeting ANGPTL3 with a one-time hepatic edit, CRISPR Therapeutics is positioning for durable risk-factor control without adherence friction. The move also exploits a clear competitive opening: monoclonal anti-ANGPTL3 (evinacumab) is IV and niche; earlier antisense efforts against ANGPTL3 were curtailed on safety grounds; and rival in vivo gene-editing efforts in cardiometabolic disease have faced early safety questions. The decision to lead with severe, refractory populations mirrors the regulatory playbook for PCSK9 therapies. It could allow initial approval based on surrogate endpoints, while deferring outcomes trials needed for broader primary prevention claims.
For trial operators and sites, the operational footprint looks more like gene therapy than cardiology pharma: single-visit IV administration, premedication and infusion monitoring, frequent early LFT checks, and long-term follow-up typical of permanent gene edits. Hepatology-capable centers and cardiometabolic clinics with infusion infrastructure will be at an advantage. CROs should anticipate small, high-risk cohorts, central lab-heavy designs, and mandated long-term safety registries. Background lipid-lowering will complicate endpoint interpretation but also enables real-world layering; notably, two participants on PCSK9 inhibitors achieved LDL reductions of over 80%, hinting at combinability but underscoring the need for standardized background therapy in later phases. For payers and health systems, the economics will pivot on durability: a single administration competing with lifelong injectables could be compelling, but irreversibility will sharpen scrutiny of off-target risks and hepatic safety.
The next test is durability and scale. The dataset is small, early, and concentrated at 30–60 days; regulators and clinicians will expect sustained suppression of ANGPTL3 and lipids out to 6–12 months with stable liver signals, along with expanded safety characterization across diverse metabolic profiles. Dose optimization between 0.6–0.8 mg/kg, redosing feasibility in the context of Cas9 immunity, and off-target edit profiling will be pivotal. Watch for Phase 1b designs that lock background therapy, enrich for event-prone phenotypes, and incorporate adaptive dose selection. If the signal holds and safety remains clean, CRISPR Therapeutics could move toward a surrogate-based filing in a high-risk niche while standing up an outcomes program—setting up a head-to-head contest with chronic biologics and the first real-world test of one-time gene editing in cardiovascular prevention.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
